Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
197 hedge funds and large institutions have $3.16B invested in Impax Laboratories, Inc. in 2015 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 79 reducing their positions, and 34 closing their positions.
103% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $7.7M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
3% more capital invested
Capital invested by funds: $3.05B → $3.16B (+$104M)
0% more funds holding
Funds holding: 197 → 197 (0)
0% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 34
16% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hound Partners
New York
|
+$232M |
| 2 |
PCM
Pennant Capital Management
Summit,
New Jersey
|
+$56M |
| 3 |
SCA
Southpoint Capital Advisors
New York
|
+$47.5M |
| 4 |
HM
HealthCor Management
New York
|
+$26.1M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$74.3M |
| 2 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$59.1M |
| 3 |
Neuberger Berman Group
New York
|
-$38.4M |
| 4 |
Jennison Associates
New York
|
-$31.6M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
HSBC Holdings
London,
United Kingdom
| – | -$208K | -4,425 | Closed |
|
|
CLOS
227
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$201K | -4,296 | Closed |
|
|
CMBA
228
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$160K | -3,405 | Closed |
|
229
Simplex Trading
Chicago,
Illinois
| – | -$144K | -3,024 | Closed |
|
230
Creative Planning
Overland Park,
Kansas
| – | -$3K | -54 | Closed |
|
IPXL Hedge Fund Activity: Q2 2015 in Review
197 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q2 2015, worth a combined $3.16B — up 3.4% from $3.05B a quarter earlier.
Fund positioning in IPXL was balanced in Q2 2015: 34 funds opened new positions, 34 closed out, 66 added to existing stakes and 79 trimmed.
The largest buyer was Hound Partners, adding an estimated $232M. The largest seller was Fidelity Investments, cutting an estimated $74.3M.
- 197 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $3.16B of Impax Laboratories, Inc. stock for Q2 2015, up 3.4% quarter-over-quarter.
- 34 funds opened new Impax Laboratories, Inc. positions in Q2 2015 and 34 closed out, a net change of 0 holders.
- The largest Impax Laboratories, Inc. buyer in Q2 2015 was Hound Partners, an estimated $232M added.
- The largest Impax Laboratories, Inc. seller in Q2 2015 was Fidelity Investments, an estimated $74.3M sold.
Based on aggregated 13F filings for Q2 2015.